Aventis Loses Second Lovenox Patent Reissuance Bid

Law360, New York (July 27, 2004, 12:00 AM EDT) -- French drug maker Aventis SA has vowed to continue fighting for a reissuance of a patent for its best-selling anti-blood clotting drug Lovenox, even though its application was rejected twice by the U.S. Patent & Trademark Office.

Aventis said Tuesday it received a second rejection from the USPTO on its application for reissuance of U.S. patent no. 5,389,618 ('618 patent), which covers Lovenox.

Aventis filed an application with the USPTO to try to reissue the ‘618 patent in May 2003. Reissuance applications are typically used to...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.